GARDASIL prevents cervical cancer, pre-cancerous and low-grade lesions and genital warts caused by HPV types 6, 11, 16 and 18

A recent article in the Times 4 September 2006, carried the headline "Cervical cancer vaccine may save 800 lives a year". 

This vaccine is available at Breakspear Hospital and can protect girls/women against infection from the human papilloma virus (HPV) which causes cervical cancer.

HPV is the virus that causes cell changes that can lead to cervical cancer. It is a common virus that is mainly passed on during sexual intercourse.

An important point to emphasize is that this vaccine is not a treatment for cervical cancer, high-grade cervical, vulvar and vaginal dysplastic lesions or genital warts, neither is it a substitute for routine cervical screenings. It is, however, the first vaccine developed to prevent cancer that is approved.

The vaccine we offer, GARDASIL, is a non-infectious vaccine and helps prevent diseases caused by HPV types 6,11,16 and 18, which may cause up approximately 70% of cases of cervical cancer.

The vaccine works best when given before one has contracted HPV. GARDASIL is approved for 9 - 26 year old girls and women.

The primary vaccination series consists of 3 separate doses, given at intervals of 0, 2, 6 months. Alternatively the second dose should be administered at least 1 month after the first dose and the third dose should be administered at least 3 months after the second dose. All 3 doses should be given within a 1-year period.

The course of 3 vaccinations is currently £450.00.* The initial visit and vaccination will include a brief consultation with a doctor.

For more information or to book an initial consultation, please contact Reception 01442 261 333.

For more information about GARDASIL, visit Merck & Co's press release.

*Breakspear Medical Group reserves the right to alter prices without notice.